1-20 of 29
Peter J. O’Dwyer
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase II Study of Palbociclib in Patients with Tumors with CDK4 or CDK6 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1C

Mark H. O’Hara, Opeyemi Jegede, Mark A. Dickson, Angela M. DeMichele, Richard Piekarz, Robert J. Gray, Victoria Wang, Lisa M. McShane, Lawrence V. Rubinstein, David R. Patton, P. Mickey Williams, Stanley R. Hamilton, Adedayo Onitilo, James V. Tricoli, Barbara A. Conley, Carlos L. Arteaga, Lyndsay N. Harris, Peter J. O’Dwyer, Alice P. Chen, Keith T. Flaherty
Journal: Clinical Cancer Research
Clin Cancer Res (2025) 31 (1): 56–64.
https://doi.org/10.1158/1078-0432.CCR-24-0036
Published: 06 January 2025
View article titled, Phase II Study of Palbociclib in Patients with Tumors with CDK4 or CDK6 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1C
Open the PDF for Phase II Study of Palbociclib in Patients with Tumors with CDK4 or CDK6 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1C in another window
Includes: Supplementary data
Journal Articles

Next generation sequencing-based MSI scoring predict benefit in mismatch repair deficient tumors treated with nivolumab: follow-up on NCI-MATCH arm Z1D

Jonathan D. Schoenfeld, Nilofer S. Azad, Jacob Gross, Li Chen, Michael J. Overman, Katrina Kao, Latifa F. Jackson, Donna Brunnquell, Xiangning Bu, Christina Coppola, Ping Guan, Jennifer Lee, David Sims, Rebecca Fuchs, Jason L. Weirather, Kathleen L. Pfaff, Lauren Gunasti, Srin Ranasinghe, Stanley R. Hamilton, Victoria Wang, Peter J. O'Dwyer, Catherine J. Wu, Scott J. Rodig, David R. Patton, Lyndsay Harris
Journal: Clinical Cancer Research
Clin Cancer Res (2024)
https://doi.org/10.1158/1078-0432.CCR-24-0427
Published: 13 December 2024
View article titled, Next generation sequencing-based MSI scoring predict benefit in mismatch repair deficient tumors treated with nivolumab: follow-up on NCI-MATCH arm Z1D
Open the PDF for Next generation sequencing-based MSI scoring predict benefit in mismatch repair deficient tumors treated with nivolumab: follow-up on NCI-MATCH arm Z1D in another window
Includes: Supplementary data
Journal Articles

Trastuzumab and Pertuzumab in Patients with Non-Breast/Gastroesophageal HER2-Amplified Tumors: Results from the NCI–MATCH ECOG–ACRIN Trial (EAY131) Subprotocol J

Roisin M. Connolly, Victoria Wang, David M. Hyman, Petros Grivas, Edith P. Mitchell, John J. Wright, Elad Sharon, Robert J. Gray, Lisa M. McShane, Larry V. Rubinstein, David R. Patton, P. Mickey Williams, Stanley R. Hamilton, Jue Wang, Kari B. Wisinski, James V. Tricoli, Barbara A. Conley, Lyndsay N. Harris, Carlos L. Arteaga, Peter J. O'Dwyer, Alice P. Chen, Keith T. Flaherty
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (7): 1273–1280.
https://doi.org/10.1158/1078-0432.CCR-23-0633
Published: 01 April 2024
View article titled, Trastuzumab and Pertuzumab in Patients with Non-Breast/Gastroesophageal <em>HER2</em>-Amplified Tumors: Results from the NCI–MATCH ECOG–ACRIN Trial (EAY131) Subprotocol J
Open the PDF for Trastuzumab and Pertuzumab in Patients with Non-Breast/Gastroesophageal <em>HER2</em>-Amplified Tumors: Results from the NCI–MATCH ECOG–ACRIN Trial (EAY131) Subprotocol J in another window
Includes: Supplementary data
Journal Articles

The New NCI Precision Medicine Trials

Lyndsay N. Harris, Charles D. Blanke, Harry P. Erba, James M. Ford, Robert J. Gray, Michael L. LeBlanc, Siwen Hu-Lieskovan, Mark R. Litzow, Selina M. Luger, Funda Meric-Bernstam, Peter J. O'Dwyer, Megan K.D. Othus, Katerina Politi, Lois E. Shepherd, Carmen J. Allegra, Helen X. Chen, S. Percy Ivy, Larissa A. Korde, Richard F. Little, Lisa M. McShane, Jeffrey A. Moscow, David R. Patton, Magdalena Thurin, Laura M. Yee, James H. Doroshow
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (23): 4728–4732.
https://doi.org/10.1158/1078-0432.CCR-23-0917
Published: 01 December 2023
View article titled, The New NCI Precision Medicine Trials
Open the PDF for The New NCI Precision Medicine Trials in another window
Journal Articles

National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH)

Funda Meric-Bernstam, James M. Ford, Peter J. O'Dwyer, Geoffrey I. Shapiro, Lisa M. McShane, Boris Freidlin, Roisin E. O'Cearbhaill, Suzanne George, Julia Glade-Bender, Gary H. Lyman, James V. Tricoli, David Patton, Stanley R. Hamilton, Robert J. Gray, Douglas S. Hawkins, Bhanumati Ramineni, Keith T. Flaherty, Petros Grivas, Timothy A. Yap, Jordan Berlin, James H. Doroshow, Lyndsay N. Harris, Jeffrey A. Moscow
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (8): 1412–1422.
https://doi.org/10.1158/1078-0432.CCR-22-3334
Published: 14 April 2023
View article titled, National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH)
Open the PDF for National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH) in another window
Includes: Supplementary data
Journal Articles

Phase II Study of Palbociclib (PD-0332991) in CCND1, 2, or 3 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1B

Amy S. Clark, Fangxin Hong, Richard S. Finn, Angela M. DeMichele, Edith P. Mitchell, James Zwiebel, Fernanda I. Arnaldez, Robert J. Gray, Victoria Wang, Lisa M. McShane, Larry V. Rubinstein, David Patton, P. Mickey Williams, Stanley R. Hamilton, Mehmet S. Copur, Samer S. Kasbari, Ravneet Thind, Barbara A. Conley, Carlos L. Arteaga, Peter J. O'Dwyer, Lyndsay N. Harris, Alice P. Chen, Keith T. Flaherty
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (8): 1477–1483.
https://doi.org/10.1158/1078-0432.CCR-22-2150
Published: 14 April 2023
View article titled, Phase II Study of Palbociclib (PD-0332991) in <em>CCND1</em>, <em>2</em>, or <em>3</em> Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1B
Open the PDF for Phase II Study of Palbociclib (PD-0332991) in <em>CCND1</em>, <em>2</em>, or <em>3</em> Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1B in another window
Includes: Supplementary data
Journal Articles

Differential Outcomes in Codon 12/13 and Codon 61 NRAS-Mutated Cancers in the Phase II NCI-MATCH Trial of Binimetinib in Patients with NRAS-Mutated Tumors

James M. Cleary, Victoria Wang, Rebecca S. Heist, E. Scott Kopetz, Edith P. Mitchell, James A. Zwiebel, Kevin S. Kapner, Helen X. Chen, Shuli Li, Robert J. Gray, Lisa M. McShane, Larry V. Rubinstein, David R. Patton, Funda Meric-Bernstam, Melissa S. Dillmon, P. Mickey Williams, Stanley R. Hamilton, Barbara A. Conley, Andrew J. Aguirre, Peter J. O'Dwyer, Lyndsay N. Harris, Carlos L. Arteaga, Alice P. Chen, Keith T. Flaherty
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (11): 2996–3004.
https://doi.org/10.1158/1078-0432.CCR-21-0066
Published: 01 June 2021
View article titled, Differential Outcomes in Codon 12/13 and Codon 61 <em>NRAS</em>-Mutated Cancers in the Phase II NCI-MATCH Trial of Binimetinib in Patients with <em>NRAS</em>-Mutated Tumors
Open the PDF for Differential Outcomes in Codon 12/13 and Codon 61 <em>NRAS</em>-Mutated Cancers in the Phase II NCI-MATCH Trial of Binimetinib in Patients with <em>NRAS</em>-Mutated Tumors in another window
Includes: Supplementary data
Journal Articles

Open-label, Phase I Study of Nivolumab Combined with nab-Paclitaxel Plus Gemcitabine in Advanced Pancreatic Cancer

Zev A. Wainberg, Howard S. Hochster, Edward J. Kim, Ben George, Aparna Kaylan, E. Gabriela Chiorean, David M. Waterhouse, Martin Guiterrez, Aparna Parikh, Rishi Jain, Daniel Ricardo Carrizosa, Hatem H. Soliman, Thomas Lila, David J. Reiss, Daniel W. Pierce, Rafia Bhore, Sibabrata Banerjee, Larry Lyons, Chrystal U. Louis, Teng Jin Ong, Peter J. O'Dwyer
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (18): 4814–4822.
https://doi.org/10.1158/1078-0432.CCR-20-0099
Published: 15 September 2020
View article titled, Open-label, Phase I Study of Nivolumab Combined with <em>nab</em>-Paclitaxel Plus Gemcitabine in Advanced Pancreatic Cancer
Open the PDF for Open-label, Phase I Study of Nivolumab Combined with <em>nab</em>-Paclitaxel Plus Gemcitabine in Advanced Pancreatic Cancer in another window
Includes: Supplementary data
Journal Articles

BRAF-Mutant Transcriptional Subtypes Predict Outcome of Combined BRAF, MEK, and EGFR Blockade with Dabrafenib, Trametinib, and Panitumumab in Patients with Colorectal Cancer

Gary Middleton, Yiqun Yang, Catarina D. Campbell, Thierry André, Chloe E. Atreya, Jan H.M. Schellens, Takayuki Yoshino, Johanna C. Bendell, Antoine Hollebecque, Autumn J. McRee, Salvatore Siena, Michael S. Gordon, Josep Tabernero, Rona Yaeger, Peter J. O'Dwyer, Filip De Vos, Eric Van Cutsem, John M. Millholland, Jan C. Brase, Fatima Rangwala, Eduard Gasal, Ryan B. Corcoran
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (11): 2466–2476.
https://doi.org/10.1158/1078-0432.CCR-19-3579
Published: 01 June 2020
View article titled, <em>BRAF</em>-Mutant Transcriptional Subtypes Predict Outcome of Combined BRAF, MEK, and EGFR Blockade with Dabrafenib, Trametinib, and Panitumumab in Patients with Colorectal Cancer
Open the PDF for <em>BRAF</em>-Mutant Transcriptional Subtypes Predict Outcome of Combined BRAF, MEK, and EGFR Blockade with Dabrafenib, Trametinib, and Panitumumab in Patients with Colorectal Cancer in another window
Includes: Supplementary data
Journal Articles

Trametinib Activity in Patients with Solid Tumors and Lymphomas Harboring BRAF Non-V600 Mutations or Fusions: Results from NCI-MATCH (EAY131)

Douglas B. Johnson, Fengmin Zhao, Marcus Noel, Gregory J. Riely, Edith P. Mitchell, John J. Wright, Helen X. Chen, Robert J. Gray, Shuli Li, Lisa M. McShane, Larry V. Rubinstein, David Patton, P. Mickey Williams, Stanly R. Hamilton, Barbara A. Conley, Carlos L. Arteaga, Lyndsay N. Harris, Peter J. O'Dwyer, Alice P. Chen, Keith T. Flaherty
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (8): 1812–1819.
https://doi.org/10.1158/1078-0432.CCR-19-3443
Published: 15 April 2020
View article titled, Trametinib Activity in Patients with Solid Tumors and Lymphomas Harboring BRAF Non-V600 Mutations or Fusions: Results from NCI-MATCH (EAY131)
Open the PDF for Trametinib Activity in Patients with Solid Tumors and Lymphomas Harboring BRAF Non-V600 Mutations or Fusions: Results from NCI-MATCH (EAY131) in another window
Includes: Supplementary data
Journal Articles

Dynamic Contrast-enhanced MRI Detects Responses to Stroma-directed Therapy in Mouse Models of Pancreatic Ductal Adenocarcinoma

Jianbo Cao, Stephen Pickup, Cynthia Clendenin, Barbara Blouw, Hoon Choi, David Kang, Mark Rosen, Peter J. O'Dwyer, Rong Zhou
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (7): 2314–2322.
https://doi.org/10.1158/1078-0432.CCR-18-2276
Published: 01 April 2019
View article titled, Dynamic Contrast-enhanced MRI Detects Responses to Stroma-directed Therapy in Mouse Models of Pancreatic Ductal Adenocarcinoma
Open the PDF for Dynamic Contrast-enhanced MRI Detects Responses to Stroma-directed Therapy in Mouse Models of Pancreatic Ductal Adenocarcinoma in another window
Includes: Supplementary data
Journal Articles

Combination Paclitaxel and Palbociclib: Results of a Phase I Trial in Advanced Breast Cancer

Amy S. Clark, Nicholas P. McAndrew, Andrea Troxel, Michael Feldman, Priti Lal, Mark Rosen, Jessica Burrell, Colleen Redlinger, Maryann Gallagher, Angela R. Bradbury, Susan M. Domchek, Kevin R. Fox, Peter J. O'Dwyer, Angela M. DeMichele
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (7): 2072–2079.
https://doi.org/10.1158/1078-0432.CCR-18-0790
Published: 01 April 2019
View article titled, Combination Paclitaxel and Palbociclib: Results of a Phase I Trial in Advanced Breast Cancer
Open the PDF for Combination Paclitaxel and Palbociclib: Results of a Phase I Trial in Advanced Breast Cancer in another window
Includes: Supplementary data
Journal Articles

First-in-Human Phase I Study of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase-1 Epacadostat (INCB024360) in Patients with Advanced Solid Malignancies

Gregory L. Beatty, Peter J. O'Dwyer, Jason Clark, Jack G. Shi, Kevin J. Bowman, Peggy A. Scherle, Robert C. Newton, Richard Schaub, Janet Maleski, Lance Leopold, Thomas F. Gajewski
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (13): 3269–3276.
https://doi.org/10.1158/1078-0432.CCR-16-2272
Published: 02 July 2017
View article titled, First-in-Human Phase I Study of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase-1 Epacadostat (INCB024360) in Patients with Advanced Solid Malignancies
Open the PDF for First-in-Human Phase I Study of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase-1 Epacadostat (INCB024360) in Patients with Advanced Solid Malignancies in another window
Journal Articles

Inhibition of JNK Sensitizes Hypoxic Colon Cancer Cells to DNA-Damaging Agents

Irina A. Vasilevskaya, Muthu Selvakumaran, Lucia Cabal Hierro, Sara R. Goldstein, Jeffrey D. Winkler, Peter J. O'Dwyer
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (18): 4143–4152.
https://doi.org/10.1158/1078-0432.CCR-15-0352
Published: 14 September 2015
View article titled, Inhibition of JNK Sensitizes Hypoxic Colon Cancer Cells to DNA-Damaging Agents
Open the PDF for Inhibition of JNK Sensitizes Hypoxic Colon Cancer Cells to DNA-Damaging Agents in another window
Includes: Supplementary data
Journal Articles

A Phase I Study of an Agonist CD40 Monoclonal Antibody (CP-870,893) in Combination with Gemcitabine in Patients with Advanced Pancreatic Ductal Adenocarcinoma

Gregory L. Beatty, Drew A. Torigian, E. Gabriela Chiorean, Babak Saboury, Alex Brothers, Abass Alavi, Andrea B. Troxel, Weijing Sun, Ursina R. Teitelbaum, Robert H. Vonderheide, Peter J. O'Dwyer
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (22): 6286–6295.
https://doi.org/10.1158/1078-0432.CCR-13-1320
Published: 14 November 2013
View article titled, A Phase I Study of an Agonist CD40 Monoclonal Antibody (CP-870,893) in Combination with Gemcitabine in Patients with Advanced Pancreatic Ductal Adenocarcinoma
Open the PDF for A Phase I Study of an Agonist CD40 Monoclonal Antibody (CP-870,893) in Combination with Gemcitabine in Patients with Advanced Pancreatic Ductal Adenocarcinoma in another window
Includes: Supplementary data
Journal Articles

Autophagy Inhibition Sensitizes Colon Cancer Cells to Antiangiogenic and Cytotoxic Therapy

Muthu Selvakumaran, Ravi K. Amaravadi, Irina A. Vasilevskaya, Peter J. O'Dwyer
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (11): 2995–3007.
https://doi.org/10.1158/1078-0432.CCR-12-1542
Published: 30 May 2013
View article titled, Autophagy Inhibition Sensitizes Colon Cancer Cells to Antiangiogenic and Cytotoxic Therapy
Open the PDF for Autophagy Inhibition Sensitizes Colon Cancer Cells to Antiangiogenic and Cytotoxic Therapy in another window
Includes: Supplementary data
Journal Articles

Sorafenib in Combination with Oxaliplatin, Leucovorin, and Fluorouracil (Modified FOLFOX6) as First-line Treatment of Metastatic Colorectal Cancer: The RESPECT Trial

Josep Tabernero, Rocio Garcia-Carbonero, James Cassidy, Alberto Sobrero, Eric Van Cutsem, Claus-Henning Köhne, Sabine Tejpar, Oleg Gladkov, Irina Davidenko, Ramon Salazar, Liubov Vladimirova, Sergey Cheporov, Olga Burdaeva, Fernando Rivera, Leslie Samuel, Irina Bulavina, Vanessa Potter, Yu-Lin Chang, Nathalie A. Lokker, Peter J. O'Dwyer
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (9): 2541–2550.
https://doi.org/10.1158/1078-0432.CCR-13-0107
Published: 30 April 2013
View article titled, Sorafenib in Combination with Oxaliplatin, Leucovorin, and Fluorouracil (Modified FOLFOX6) as First-line Treatment of Metastatic Colorectal Cancer: The RESPECT Trial
Open the PDF for Sorafenib in Combination with Oxaliplatin, Leucovorin, and Fluorouracil (Modified FOLFOX6) as First-line Treatment of Metastatic Colorectal Cancer: The RESPECT Trial in another window
Includes: Supplementary data
Journal Articles

Association between VEGF Splice Isoforms and Progression-Free Survival in Metastatic Colorectal Cancer Patients Treated with Bevacizumab

David O. Bates, Paul J. Catalano, Kirsty E. Symonds, Alex H.R. Varey, Pramila Ramani, Peter J. O'Dwyer, Bruce J. Giantonio, Neal J. Meropol, Al Bowen Benson, Steven J. Harper
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (22): 6384–6391.
https://doi.org/10.1158/1078-0432.CCR-12-2223
Published: 14 November 2012
View article titled, Association between VEGF Splice Isoforms and Progression-Free Survival in Metastatic Colorectal Cancer Patients Treated with Bevacizumab
Open the PDF for Association between VEGF Splice Isoforms and Progression-Free Survival in Metastatic Colorectal Cancer Patients Treated with Bevacizumab in another window
Includes: Supplementary data
Journal Articles

Phase I, Dose-Escalation Trial of the Oral Cyclin-Dependent Kinase 4/6 Inhibitor PD 0332991, Administered Using a 21-Day Schedule in Patients with Advanced Cancer

Keith T. Flaherty, Patricia M. LoRusso, Angela DeMichele, Vandana G. Abramson, Rachel Courtney, Sophia S. Randolph, M. Naveed Shaik, Keith D. Wilner, Peter J. O'Dwyer, Gary K. Schwartz
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (2): 568–576.
https://doi.org/10.1158/1078-0432.CCR-11-0509
Published: 16 January 2012
View article titled, Phase I, Dose-Escalation Trial of the Oral Cyclin-Dependent Kinase 4/6 Inhibitor PD 0332991, Administered Using a 21-Day Schedule in Patients with Advanced Cancer
Open the PDF for Phase I, Dose-Escalation Trial of the Oral Cyclin-Dependent Kinase 4/6 Inhibitor PD 0332991, Administered Using a 21-Day Schedule in Patients with Advanced Cancer in another window
Includes: Supplementary data
Journal Articles

Phase II Trial of Temozolomide and Sorafenib in Advanced Melanoma Patients with or without Brain Metastases

Ravi K. Amaravadi, Lynn M. Schuchter, David F. McDermott, Amy Kramer, Lydia Giles, Kristi Gramlich, Mary Carberry, Andrea B. Troxel, Richard Letrero, Katherine L. Nathanson, Michael B. Atkins, Peter J. O'Dwyer, Keith T. Flaherty
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (24): 7711–7718.
https://doi.org/10.1158/1078-0432.CCR-09-2074
Published: 14 December 2009
View article titled, Phase II Trial of Temozolomide and Sorafenib in Advanced Melanoma Patients with or without Brain Metastases
Open the PDF for Phase II Trial of Temozolomide and Sorafenib in Advanced Melanoma Patients with or without Brain Metastases in another window